The biotech start-up Colossal Biosciences, led by founder Ben Lamm, has announced a breakthrough: a 3D-printed artificial egg that incubated healthy chicken chicks in a Dallas laboratory. The device—described by staff as a honeycomb-backed, clear-topped pod—lets researchers observe an embryo as it develops while supplying oxygen and nutrients in ways that mimic a natural shell. Colossal presents this outcome as a crucial proof point for larger ambitions, including an eventual artificial womb for mammals and projects to resurrect extinct birds like the dodo and the giant moa.
Colossal’s work sits at the intersection of conservation biology and speculative reproductive engineering. The company’s public mission is de-extinction—using gene editing to modify living relatives of extinct animals, place that edited DNA into embryos, and bring those embryos to term. Because traditional surrogate strategies are slow and limited for population-scale restoration, Colossal argues that scalable ex utero systems are necessary to repopulate species and accelerate conservation outcomes.
From concept to company: how Colossal aims to scale reproduction
Colossal launched with high-profile backers and an audacious agenda: reviving species such as the woolly mammoth and the dire wolf. Founder Ben Lamm, who previously built and sold multiple technology ventures including an AI defense firm, partnered with geneticists and synthetic-biology leaders to pursue that vision. The team follows a three-step technical roadmap: design the target genome with gene editing, create edited embryos, and provide an environment for gestation without relying solely on living animals as surrogates. Investors have supported this approach; the company has raised substantial capital, which Colossal says gives it flexibility to work outside some of the strictest regulatory pathways that apply to human reproductive medicine.
What the artificial egg is and why it matters
The prototype device combines a 3D-printed frame with a permeable surface engineered to let oxygen in while retaining the egg’s internal fluids. Colossal researchers describe a honeycomb or hexagonal base and a clear dome that offers a visual window into embryonic growth. The unit’s design addresses several technical constraints: controlled gas exchange, moisture retention, and real-time observation. According to the company, roughly two dozen chicks have hatched from those units and now live on Colossal’s facility, where teams will monitor their health and reproductive viability before attempting larger or genetically edited avian embryos intended to resemble extinct species.
Scaling to larger species
Birds like the dodo and the moa present unique challenges because no extant species can physically carry their embryos. That is why Colossal began with chickens as a model: to map how to deliver nutrients, manage gas exchange, and tune environmental variables across development. The company says the lessons from the artificial egg will inform subsequent systems—a placenta interface that mimics maternal exchange, and ultimately a mammalian artificial womb—with the intent to work progressively from small to larger animals if each stage proves viable.
Scientific limits and ethical debates
Despite the dramatic images of embryos moving beneath a clear dome, many researchers caution that the leap from bird eggs to full mammalian gestation—and certainly to human pregnancy replacement—is enormous. Experts emphasize that engineering functional analogs for the placenta, the uterine lining and the dynamic hormonal signaling of pregnancy remain unresolved technical problems. Skeptics note that existing research on premature mammals and prior cloning attempts reveal high failure and mortality rates, and they warn that welfare risks must be weighed against scientific goals.
Regulation, welfare, and social implications
Colossal stresses that it is not developing systems for human gestation, and that this focus reduces regulatory friction compared with human reproductive technologies. Still, critics raise moral concerns. Past efforts to resurrect extinct animals, such as the Pyrenean ibex cloning experiment, involved hundreds of embryo insertions and very low live-birth success, fueling arguments about animal suffering. Meanwhile, proponents in tech and pronatalist circles have hailed the idea of decoupling pregnancy from bodies as socially transformative, and some backers anticipate licensing Colossal’s advances to groups working on human fertility. These competing perspectives make the project both scientifically intriguing and ethically charged.
Colossal’s artificial egg shows how a concrete engineering advance can catalyze debate: supporters see a tool for conservation and reproductive innovation, while critics point to technical gaps and welfare costs that remain unresolved. The company’s next steps—validating long-term health, scaling to larger embryos, and refining interfaces that replicate maternal exchanges—will determine whether this proof of concept becomes a platform for responsible species recovery or a controversial detour in biotechnology.
